SCHEMBL14711587

SCHEMBL14711587

CC(OC(=O)Nc1ccccc1-c1ccc(-c2ccc(CC(=O)O)cc2)cc1)c1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 7/20 0.66
LPAR3 Q9UBY5 4/20 0.61
LPAR2 Q9HBW0 1/20 0.46
HTT P42858 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
LMNA P02545 3/20 0.46
GAA P10253 2/20 0.46
ABCC4 O15439 1/20 0.46
TSHR P16473 1/20 0.46
PTGS1 P23219 1/20 0.46
MAPT P10636 2/20 0.45
KCNQ2 O43526 1/20 0.45
ALDH1A1 P00352 3/20 0.44
HPGD P15428 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
NR1H4 Q96RI1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14711583 0.87 LPAR1 (0.65) LPAR1LPAR3LPAR2HTTLMNA
SCHEMBL15013269 0.87 LPAR1 (0.62) LPAR1LPAR3LPAR2HTTLMNA
SCHEMBL14711146 0.87 LPAR1 (0.67) LPAR1LPAR3LPAR2HTTLMNA
SCHEMBL14711586 0.86 LPAR1 (0.64) LPAR1LPAR3LPAR2ALDH1A1
SCHEMBL9915918 0.84 LPAR1 (0.52) LPAR1LPAR3HTTL3MBTL1LMNA
SCHEMBL14711902 0.84 LPAR1 (0.64) LPAR1LPAR3LPAR2HTTLMNA
SCHEMBL15008859 0.83 LPAR1 (0.66) LPAR1LPAR3LPAR2HTTLMNA
SCHEMBL15013444 0.83 LPAR1 (0.63) LPAR1LPAR3LPAR2HTTLMNA
SCHEMBL14711597 0.83 LPAR1 (0.63) LPAR1LPAR3LPAR2HTTLMNA
SCHEMBL14711142 0.81 LPAR1 (0.66) LPAR1LPAR3LPAR2HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 US disclosed
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 US disclosed
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-03-21 US disclosed
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-03-21 US disclosed
WO-2013025733-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR5 LPAR1 1/4885LPAR3 5/4885LPAR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.